Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib.
Reinisch W, Serone A, Hébuterne X, Kühbacher T, Kłopocka M, Roblin X, Brodbeck J, Etchevers K, Galien R, Grant E, Tasset C, Yoon OK, Zaboli S, Vermeire S. Reinisch W, et al. Among authors: roblin x. Tissue Barriers. 2023 Apr 3;11(2):2088961. doi: 10.1080/21688370.2022.2088961. Epub 2022 Jun 28. Tissue Barriers. 2023. PMID: 35762272 Free PMC article. Clinical Trial.
Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.
Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, Roblin X, Trang C, Bourreille A, Babouri A, Bretagne JF, Siproudhis L, Peyrin-Biroulet L. Bouguen G, et al. Among authors: roblin x. Inflamm Bowel Dis. 2015 May;21(5):1047-53. doi: 10.1097/MIB.0000000000000359. Inflamm Bowel Dis. 2015. PMID: 25803504
Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L, Salleron J, Filippi J, Reenaers C, Antunes O, Filipe V, Louis E, Hébuterne X, Roblin X. Peyrin-Biroulet L, et al. Among authors: roblin x. J Crohns Colitis. 2016 May;10(5):516-24. doi: 10.1093/ecco-jcc/jjw008. Epub 2016 Jan 22. J Crohns Colitis. 2016. PMID: 26802084 Free PMC article.
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, Klopocka M, Goldis A, Wisniewska-Jarosinska M, Baranovsky A, Sike R, Stoyanova K, Tasset C, Van der Aa A, Harrison P. Vermeire S, et al. Among authors: roblin x. Lancet. 2017 Jan 21;389(10066):266-275. doi: 10.1016/S0140-6736(16)32537-5. Epub 2016 Dec 15. Lancet. 2017. PMID: 27988142 Clinical Trial.
Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease.
Boube M, Laharie D, Nancey S, Hebuterne X, Fumery M, Pariente B, Roblin X, Peyrin-Biroulet L, Minet-Quinard R, Pereira B, Bommelaer G, Buisson A; POPCUR study group. Boube M, et al. Among authors: roblin x. Dig Liver Dis. 2020 Jul;52(7):740-744. doi: 10.1016/j.dld.2020.03.020. Epub 2020 May 20. Dig Liver Dis. 2020. PMID: 32444250 Clinical Trial.
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.
Buisson A, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, Fumery M, Laharie D, Roblin X, Bommelaer G, Pereira B, Peyrin-Biroulet L, Vuitton L; USTEK Post-Op study group. Buisson A, et al. Among authors: roblin x. United European Gastroenterol J. 2021 Jun;9(5):552-560. doi: 10.1002/ueg2.12068. Epub 2021 May 5. United European Gastroenterol J. 2021. PMID: 33951350 Free PMC article.
353 results